The online home of Neurology Reviews

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Alemtuzumab increases the likelihood of disability improvement in MS

Publish date:: May 22, 2019

Key clinical point: More than one-third of patients achieved 6-month confirmed disability improvement over 6 years.

Major finding: Patients with baseline EDSS scores between 4.0 and 4.5 are most likely to achieve disability improvement.

Study details: An analysis of pooled data for 565 patients in the CARE-MS I and CARE-MS II studies.

Disclosures: Sanofi, Bayer HealthCare Pharmaceuticals supported the study.

Citation:

Hunter SF et al. CMSC 2019. Abstract DXT08.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,